Clear Perspective Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Clear Perspective Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-300	Closed	-$18K	–	363
2018 Q2	$18K	Hold	300	–	–	0.01%	321
2018 Q1	$17K	Hold	300	–	–	0.01%	315
2017 Q4	$18K	Hold	300	–	–	0.01%	300
2017 Q3	$17K	Hold	300	–	–	0.01%	303
2017 Q2	$18K	Hold	300	–	–	0.02%	296
2017 Q1	$17K	Hold	300	–	–	0.01%	282
2016 Q4	$16K	Buy	+300	New	+$16K	0.01%	286

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Clear Perspective Advisors's PPH Position: Q3 2018 in Review

Clear Perspective Advisors sold out of VanEck Pharmaceutical ETF (PPH) in Q3 2018, closing a stake of 300 shares — an estimated $18K sold.

Clear Perspective Advisors first reported a position in PPH in Q4 2016 and held it in 7 quarters. The position peaked at $18K in Q2 2018. 44 funds tracked by Wall St. Rank hold PPH as of Q3 2018.

Clear Perspective Advisors reported no remaining VanEck Pharmaceutical ETF position as of Q3 2018 after selling out during the quarter.
Clear Perspective Advisors sold 300 VanEck Pharmaceutical ETF shares in Q3 2018, an estimated $18K.
Clear Perspective Advisors first reported a position in VanEck Pharmaceutical ETF in Q4 2016 and held it in 7 quarters.
Clear Perspective Advisors's VanEck Pharmaceutical ETF position peaked at $18K in Q2 2018.
44 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2018.

Based on Clear Perspective Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.